Aziyo Biologics, Inc. (AZYO) Misses Q3 EPS by 6c

Aziyo Biologics, Inc. (NASDAQ: AZYO) reported Q3 EPS of ($0.73), $0.06 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $5.05 million versus the consensus estimate of $12.38 million.

GUIDANCE:

Aziyo Biologics, Inc. sees FY2022 revenue of $48-50 million.

For earnings history and earnings-related data on Aziyo Biologics, Inc. (AZYO) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• UBS Upgrades Zhejiang Leapmotor Technology (9863:HK) to Buy
• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance